Lanadelumab
Lanadelumab is a monoclonal antibody medication used for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older. It works by binding to and inhibiting plasma kallikrein, an enzyme responsible for producing bradykinin, thereby reducing the frequency and severity of HAE attacks.
Lanadelumab is a monoclonal antibody that prevents hereditary angioedema attacks by inhibiting the enzyme that produces bradykinin.
Key facts at a glance
- ATC
- B06AC05
- RxNorm
- 2055641
- Generic
- Lanadelumab
- Class
- atc-b06
- Brands
- Takhzyro
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh potential risks to fetus; consider continuing therapy if HAE attacks pose greater risk
regular prenatal monitoring and fetal ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
second and third trimesterno adjustment needed
may continue therapy if needed for HAE prophylaxis; benefits may outweigh risks
routine prenatal care and fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
use with caution; decision to breastfeed should consider potential infant exposure
monitor infant for any adverse effects
pediatric_age
under 12 yearsnot recommended
safety and efficacy not established in children under 12 years
not applicable
pediatric_age
12 to 17 yearsno adjustment needed
approved for use in patients 12 years and older; standard dosing applies
routine clinical monitoring for efficacy and safety
geriatric
65 years and olderno adjustment needed
use standard dosing; monitor closely for adverse reactions
regular assessment of efficacy and tolerability
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno adjustment needed
no dose adjustment required for mild to moderate renal impairment
routine clinical monitoring
renal_impairment
severeno adjustment needed based on limited data
use with caution; limited data available for severe renal impairment
close clinical monitoring recommended
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno adjustment needed based on limited data
use with caution; limited clinical data in hepatic impairment
routine clinical monitoring of liver function may be considered
Use with caution and monitor for adverse effects.
hepatic_impairment
severenot recommended
not studied in severe hepatic impairment; use only if benefits outweigh risks
close monitoring recommended if used
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
FDA approval information for Lanadelumab (Takhzyro)
Drug class
Drug classification information
Indication
Therapeutic indication
Route of administration
Administration route information
Lanadelumab is indicated for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients 12 years of age and older. It is not used for acute attack treatment but rather as a long-term preventive therapy.
Lanadelumab is a fully human monoclonal antibody (IgG1/κ-light chain) that specifically binds to plasma kallikrein and inhibits its proteolytic activity. By blocking plasma kallikrein, it prevents the cleavage of high-molecular-weight kininogen (HMWK) into cleaved HMWK and bradykinin, reducing bradykinin-mediated swelling attacks.
Lanadelumab is administered as a subcutaneous injection. Common adverse reactions include injection site reactions, upper respiratory infections, and headache. Patients should be monitored for hypersensitivity reactions. It is intended for use under the guidance of a physician experienced in managing HAE.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy